Therapeutic area intelligence for Cochlear Implant with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Sound Pharmaceuticals →

Assets

SPI-1005 →

Recent signals(1)

ClinicalJune 29, 2026

SPI-1005 Trial for Adults with Cochlear Implants Shows Potential for Side Effect Management

The clinical trial aims to assess the safety and tolerability of SPI-1005 in adults receiving cochlear implants, focusing on side effects such as tinnitus and vertigo.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.